Atrovent

How to order Atrovent

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Atrovent on Prescriptsy

Atrovent is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Atrovent is the brand name for ipratropium bromide, an anticholinergic (antimuscarinic) bronchodilator prescribed for the management of chronic obstructive pulmonary disease (COPD) and as adjunctive therapy in asthma.

Ipratropium works by blocking muscarinic acetylcholine receptors in bronchial smooth muscle, which relaxes the airways and reduces excessive mucus production driven by parasympathetic nerve activity.

It has been used in clinical practice in the United Kingdom since the 1970s and remains an important component of respiratory disease management.

COPD affects approximately 1.2 million people diagnosed in England alone, with many more undiagnosed. It is the third leading cause of death worldwide.

Asthma affects around 5.4 million people in the UK, including 1.1 million children.

While short-acting beta-2 agonists (SABAs) such as salbutamol are the primary reliever medications, ipratropium provides complementary bronchodilation through a distinct pharmacological pathway and is particularly valuable in COPD, where cholinergic tone is a major contributor to airflow limitation.

This product information has been reviewed by Dr.

Claire Phipps, MBBS MRCGP (GMC 7014359), and provides a thorough clinical overview of Atrovent covering its mechanism of action, licensed indications, dosing across formulations, side effects, safety warnings and its place in UK respiratory guidelines.

Essential safety information about Atrovent

Atrovent is not a rescue inhaler. It does not work quickly enough to relieve acute breathlessness and must not replace your short-acting beta-2 agonist (salbutamol or terbutaline) for emergency relief. Three important safety points:

• Do not allow nebulised ipratropium solution to contact your eyes, this can trigger acute angle-closure glaucoma with severe eye pain, vision changes and redness requiring emergency treatment
• The Atrovent MDI contains soya lecithin, patients with soya or peanut allergy must not use this formulation and should discuss alternatives with their prescriber
• If your breathing suddenly worsens after using Atrovent (paradoxical bronchospasm), stop using it immediately, use your salbutamol reliever, and seek medical attention

Atrovent is a prescription-only medicine (POM). It should be used as part of a structured respiratory management plan developed with your GP or respiratory specialist. Continue all other prescribed inhalers and attend regular review appointments.

How Atrovent (ipratropium bromide) works

Ipratropium bromide is a synthetic quaternary ammonium derivative of atropine.

It acts as a competitive, non-selective antagonist at muscarinic acetylcholine receptors (subtypes M1, M2 and M3) in the airways.

The primary bronchodilator effect results from blocking M3 receptors on bronchial smooth muscle cells, which prevents acetylcholine-mediated contraction and allows the airways to relax and widen.

In addition to bronchial smooth muscle relaxation, ipratropium reduces parasympathetically driven mucus hypersecretion from submucosal glands in the airways.

This dual action, bronchodilation and reduction of mucus overproduction, makes it particularly useful in COPD, where both mechanisms contribute to airflow obstruction and breathlessness.

As a quaternary ammonium compound, ipratropium is poorly absorbed across biological membranes.

When inhaled, less than 10% of the dose reaches the lower airways, with the remainder deposited in the oropharynx and swallowed.

Systemic bioavailability is very low (approximately 2% of the inhaled dose), which accounts for the favourable side effect profile compared with systemic anticholinergic drugs.

The onset of bronchodilation occurs within 15 minutes of inhalation, peaks at 1-2 hours, and lasts 4-6 hours.

This slower onset compared with SABAs (5 minutes for salbutamol) is why ipratropium is not suitable as a sole rescue medication in acute breathlessness.

Licensed indications in the UK

Chronic obstructive pulmonary disease (COPD)

Ipratropium is licensed for the maintenance treatment of reversible bronchospasm associated with COPD, including chronic bronchitis and emphysema.

NICE guideline NG115 positions short-acting bronchodilators (SABA or SAMA, or both) as first-line treatment for COPD patients who remain symptomatic despite general measures.

For patients with persistent breathlessness despite a SABA alone, adding ipratropium provides additional bronchodilation through a complementary mechanism.

In current practice, long-acting muscarinic antagonists (LAMAs) such as tiotropium have largely replaced ipratropium for regular maintenance therapy due to once-daily dosing convenience, but ipratropium retains a role in acute exacerbations and in patients who do not tolerate or respond to LAMAs.

Asthma

In chronic asthma, ipratropium may be used as add-on bronchodilator therapy when inhaled corticosteroids and SABAs are insufficient.

Its role is primarily in acute severe asthma (British Thoracic Society/SIGN guideline), where nebulised ipratropium (500 micrograms) is added to nebulised salbutamol in the emergency department or ambulance setting.

This combination provides greater bronchodilation than either drug alone in acute attacks.

For routine asthma management, ipratropium is not a preferred maintenance option and is used only when other therapies are insufficient or not tolerated.

Rhinorrhoea

Ipratropium bromide is also available as a nasal spray (Rinatec) for the symptomatic relief of rhinorrhoea associated with perennial rhinitis and vasomotor rhinitis. The nasal formulation is a separate product from the inhaled bronchodilator and is prescribed under different circumstances.

Dosage and administration

Metered-dose inhaler (MDI): Atrovent MDI delivers 20 micrograms of ipratropium bromide per actuation.

The usual adult dose for COPD is 2 puffs (40 micrograms) three to four times daily, with a maximum daily dose of 12 puffs (240 micrograms).

For asthma as adjunctive therapy, 1-2 puffs three to four times daily is the standard range.

A spacer device (such as AeroChamber or Volumatic) is recommended to improve lung deposition and reduce oropharyngeal deposition.

Nebuliser solution: Atrovent nebuliser solution is available as 250 microgram/1ml and 500 microgram/2ml unit-dose vials.

For COPD maintenance, the usual dose is 250-500 micrograms nebulised up to four times daily.

In acute severe asthma or acute COPD exacerbation, 500 micrograms is nebulised alongside salbutamol (2.5-5mg).

Always use a mouthpiece for nebulisation, not a face mask, to prevent eye contact with the aerosol.

Correct inhaler technique is essential for therapeutic benefit. Many patients use their inhalers suboptimally.

Key steps for MDI use: shake the inhaler, breathe out fully, seal lips around the mouthpiece, press the canister while inhaling slowly and deeply, hold breath for up to 10 seconds, and exhale gently.

Wait at least 30 seconds between puffs. Ask your pharmacist or practice nurse for an inhaler technique check if you are unsure.

No dose adjustment is required in hepatic or renal impairment for inhaled ipratropium due to minimal systemic absorption. Elderly patients use the same dose range as younger adults.

Children may use nebulised ipratropium under specialist guidance, with the dose adjusted by age and weight.

Side effects of Atrovent

Common side effects

Ipratropium bromide has a favourable safety profile due to its low systemic absorption when inhaled. The most common side effects are anticholinergic in nature and are typically mild:

• Dry mouth (most frequent, affecting up to 10% of users), manage with water sips, sugar-free gum, or saliva substitutes
• Headache and dizziness
• Throat irritation and cough provoked by the inhaler
• Nausea and altered taste

Uncommon and serious side effects

Less commonly reported effects include palpitations, urinary retention (especially in men with pre-existing prostatic enlargement), constipation, and blurred vision. Skin rash and pruritus occur rarely.

Paradoxical bronchospasm, sudden worsening of wheeze and breathlessness immediately after inhaling, is a recognised but uncommon class effect of all inhaled bronchodilators.

The most clinically significant risk is acute angle-closure glaucoma, which has been reported when nebulised ipratropium (alone or with salbutamol) contacts the eyes.

Symptoms include severe eye pain, redness, haloes around lights, and blurred vision. This is an ophthalmological emergency requiring immediate hospital assessment.

Using a mouthpiece rather than a face mask for nebulisation virtually eliminates this risk.

Anaphylaxis and angioedema are extremely rare. Contact your GP, call NHS 111, or in an emergency call 999. Report suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Warnings, contraindications and interactions

Contraindications: known hypersensitivity to ipratropium bromide, atropine or its derivatives, or to any excipient in the formulation.

The Atrovent MDI contains soya lecithin: patients with allergy to soya, peanut, or related legumes should not use this formulation and should discuss the nebuliser solution (which does not contain soya lecithin) or alternative bronchodilators with their prescriber.

Precautions: narrow-angle glaucoma (avoid eye contact with aerosol), prostatic hyperplasia and bladder neck obstruction (risk of urinary retention), cystic fibrosis (increased susceptibility to gastrointestinal motility disturbance), and myasthenia gravis.

Ipratropium should be used with caution in these groups and patients should be counselled about relevant warning symptoms.

Drug interactions: systemic anticholinergic effects may be enhanced by concurrent use of other anticholinergic drugs including tricyclic antidepressants, antihistamines (particularly first-generation such as chlorphenamine), oxybutynin, and some antipsychotics.

While the interaction risk is low with inhaled ipratropium due to minimal systemic absorption, cumulative anticholinergic burden should be considered, particularly in elderly patients at risk of confusion, constipation, and urinary retention.

Atrovent in the context of UK respiratory guidelines

NICE guideline NG115 for COPD management recommends short-acting bronchodilators (SABA, SAMA, or combined) as initial pharmacotherapy for breathlessness.

If symptoms persist, patients step up to long-acting bronchodilators (LABA and/or LAMA) with or without inhaled corticosteroids depending on phenotype (eosinophilic versus non-eosinophilic COPD).

In this framework, Atrovent (ipratropium) serves as a step-1 maintenance option and as acute exacerbation combination therapy with salbutamol.

For asthma, the BTS/SIGN guideline and NICE guideline NG80 position ipratropium primarily in the acute severe asthma algorithm.

Nebulised ipratropium added to nebulised salbutamol is standard care in emergency departments for acute asthma attacks not responding to initial SABA therapy.

In chronic asthma, ipratropium has a limited role and is used only when standard step-up therapy (ICS, LABA, LTRA, LAMA) is inadequate.

Practical information for UK patients

Atrovent is a prescription-only medicine. The standard NHS prescription charge in England is 9.90 pounds per item. Prescriptions are free in Scotland, Wales and Northern Ireland.

Many patients with chronic respiratory disease will qualify for a medical exemption certificate or benefit from a Prescription Prepayment Certificate (PPC). Ask your pharmacist about eligibility.

Store the Atrovent MDI below 25 degrees Celsius, away from direct sunlight. Do not puncture the canister or expose it to temperatures above 50 degrees Celsius.

Nebuliser vials should be stored protected from light and used immediately after opening. Return unused inhalers and nebuliser vials to your pharmacy for safe disposal.

Sources and further reading

• Electronic Medicines Compendium (EMC), Atrovent SmPC: medicines.org.uk/emc
• British National Formulary (BNF), Ipratropium bromide: bnf.nice.org.uk
• NICE Guideline NG115, Chronic obstructive pulmonary disease: nice.org.uk/guidance/ng115
• BTS/SIGN Guideline 158, British guideline on the management of asthma: brit-thoracic.org.uk
• NHS, Ipratropium inhalers: nhs.uk/medicines/ipratropium-inhaler
• MHRA Yellow Card Scheme: yellowcard.mhra.gov.uk